Guide

Whether a cash aesthetics practice can build revenue on compounded weight-loss injections

Summary

A med spa can sell compounded semaglutide only while a federal door is open, and shortage listing is that door: federal law lets an outsourcing facility compound a drug identical or nearly identical to an approved one while that approved drug sits on FDA's shortage list at the time of compounding, distribution, and dispensing. Off the list, the exception closes, and the statute's remaining routes govern compounding from bulk drug substances. State law then decides who may prescribe and inject.

By Gale Editorial · Updated 2026-09-02. Every figure cited to a dated source. How we write.

Can a med spa still sell compounded semaglutide?

Federal law bars a compounder from making a drug that is essentially a copy of an approved one, and then carves out narrow exceptions; for an outsourcing facility, the exception that made a compounded copy lawful at all was the drug shortage list 1. So the answer is sometimes, on terms set outside the practice. Whether that exception is open on a given day is a question about a federal list nobody in the building controls.

The state layer arrives right behind it, and it varies. Who may prescribe an injectable, who may inject it, and what supervision paperwork has to exist first are answered by a medical board and a nursing board; FDA has no part in them. A program lawful in its supply can still be unlawful in its delivery.

Nothing FDA does to the shortage list changes what a state board expects of the person holding the syringe.

What the shortage list licensed, and for whom

It licensed the supplier, not the practice. Section 503B lets an outsourcing facility compound a drug that is identical or nearly identical to an approved product where that approved drug appears on FDA's drug shortage list at the time of compounding, distribution, and dispensing 1, and that is the carve-out these programs ran on. The permission attaches to the compounder's conduct on a date. A med spa buys the output of that permission and inherits its expiry.

Shortage carries a statutory meaning here. The list is the one FDA maintains under 21 U.S.C. 356e, an up-to-date public record of the drugs the agency has determined to be in shortage in the United States 2. A distributor backorder is not that list, and neither is a wholesaler's allocation notice or a supplier email describing tight supply.

The other compounding lane never had this door. A pharmacist or physician compounding under Section 503A may not make a drug essentially a copy of a commercially available product, and the statute's single escape is a change made for an identified individual patient that the prescriber determines produces a significant difference for that patient 3. There is no shortage exception in 503A at all. A practice sourcing from a traditional compounding pharmacy was never inside the shortage lane, whatever the invoice implied.

Where the statute puts each exception

An outsourcing facility whose approved drug is off the shortage list has to look at a different part of the statute, and the parts are not interchangeable. The bar on a drug identical or nearly identical to an approved product admits one exception, and it is the shortage listing itself 1. The individual-patient clinical difference sits in a separate prong, which reaches a drug whose component is a bulk drug substance that is itself a component of an approved drug, and lets it through where the prescribing practitioner determines a change produces a clinical difference for that patient 1. The clinical need Bulks List is a third thing again: it is one of the two lawful bases for compounding from a bulk substance at all, the other being that the drug made from it appears on the shortage list 1.

Neither of those is wide. A Bulks List entry is a list FDA controls. A clinical difference is a determination the prescribing practitioner makes for an individual patient 1; the statute names the determination and says nothing about where it is recorded, so a practice that wants the determination to be provable keeps it in the chart. It does not scale into a menu price.

The Bulks List is where FDA moved. In a notice dated May 1, 2026, the agency proposed not to add semaglutide, tirzepatide, or liraglutide, having tentatively found no basis to conclude that there is a clinical need for an outsourcing facility to compound using them 4. The same notice states that FDA-approved tirzepatide products are not on the drug shortage list 4.

FDA's clinical need test opens with a question about the approved drug rather than the compounded one: whether an attribute of the FDA-approved product makes it medically unsuitable to treat certain patients for a condition the agency has identified for evaluation 4. It then asks whether there is a basis to conclude that the product proposed for compounding must be produced from a bulk drug substance at all, instead of from the FDA-approved drug 4. A supplier has to clear both. Demand answers neither, and neither does price. A supplier explaining that patients cannot afford the branded product is describing a market, while the test asks about medical suitability.

The proposal is not final as of this writing in late August 2026. FDA extended the comment deadline to July 30, 2026 after receiving a request for a 60-day extension; the notice records the request's concern that the comment period as it stood was too short 5. Comments have closed, and the question now sits in a docket, FDA-2018-N-3240, that anyone can read.

Checking the status yourself, and how often

Read the list before you read the invoice. Two public documents answer the list half of this question on any given day: FDA's drug shortage list, which is the list the 503B exception names 2, and the Bulks List docket, FDA-2018-N-3240, where the clinical need proposal for semaglutide, tirzepatide, and liraglutide sits 5. Both are free to read.

A few things are worth keeping where an inquiry can find them.

1. The shortage-list status of the approved drug on the date each order was placed, saved as a dated printout. 2. The compounder's registration and the section it works under, 503A or 503B, because the two carry different rules and an invoice rarely says which. 3. The prescriber's determination for the individual patient, wherever an order rests on a clinical difference. The statute requires the determination; keeping it in the chart is what makes it provable. 4. The state authority for who prescribed and who injected, recorded by section number.

Put the recheck on a calendar. the statute ties lawfulness to the time of compounding, distribution, and dispensing 1, so a status that held when the menu was priced says nothing about the case of product arriving next month. The date a program was designed does not enter into it.

One thing this page cannot do is state today's status. Listings move, and a page written in August cannot answer a question decided by what the list says on the morning an order goes out.

Who may prescribe and inject, and on what paperwork

The state where the injection happens answers this, and it answers differently across the border. California works as one example rather than as the national rule: practicing medicine without a license there, or conspiring with, aiding, or abetting a person who does, carries a fine of up to $10,000, or up to a year in county jail, or a felony term under Penal Code section 1170(h), or the fine together with either term 6. Other states set their own penalties and their own delegation rules.

California also shows what delegation paperwork looks like where it exists. A nurse practitioner working under standardized procedures rather than independent authority has to work from a written standardized procedure jointly developed and approved by the supervising physician, the nurse practitioner, and the facility administrator or a designee, and that document names which drugs and devices may be furnished, the extent of physician supervision, and a periodic review of competence 7. A practice either holds that document or does not.

The paperwork question is separable from the supply question, so a program can clear the federal test and fail here. And ownership sits underneath both, on the same state-by-state basis: in states with a corporate practice doctrine, who owns the entity, who employs the injector and who holds clinical control are the questions it reaches.

Counsel licensed where you practice answers both from the section numbers, and the questions are narrow enough to ask precisely: which statute governs delegation of this act, and what the supervising physician's exposure is when the delegation is loose.

What a revenue line built on someone else's permission is worth

The permission belongs to a party the practice never meets, which is why the line is worth less than its margin suggests. A service line whose legality depends on a federal list can end on a publication date, with inventory bought, staff hired, and patients partway through a course. The useful move is to price it as a lane with an expiry, and to know every month how much of the practice would leave with it.

Watch how much of a month's collections one drug carries. Where most of them ride on it, the practice has a single point of failure, and prepaid packages make a closure a cash event as well as a revenue one, since refunds land in the same weeks the supply stops.

A membership panel prices on a different axis, since the DPC equation turns on how many patients the panel holds and what each pays every month, so one drug leaving the market does not empty it. Aesthetic services with no drug-supply dependency behave the same way. For a clinician who also holds payer contracts, cash lines while in network is a separate question, and the contract language usually decides it.

Referral flow without buying it is one constraint on rebuilding volume, and whether federal fraud and abuse law reaches it depends on the payer mix: where any of the practice's business is payable by a federal health care program, paying for referrals, or accepting payment for them, is where that law bites. Records are a second. A cash-only aesthetics practice may or may not sit inside HIPAA at all, so run the covered-entity test against how the practice bills today, and run it again when the billing changes.

Whatever replaces the lane, keep the file. The dated status checks, the section numbers and the signatures keep their value after the list changes.

Common questions

Registration answers a different question. A 503B outsourcing facility may compound a drug identical or nearly identical to an approved product only while that approved drug is on FDA's shortage list at the time of compounding, distribution and dispensing, and registering changes nothing about that. The clinical need Bulks List is a separate requirement, governing which bulk substances a facility may work from at all. The exception turns on a date, so record the date.

The exceptions differ. Section 503A binds a pharmacist or physician compounder, whose only escape from the essentially-a-copy prohibition is a prescriber-determined significant difference for one identified patient. Section 503B gives an outsourcing facility two lawful bases to compound from a bulk drug substance: the substance is on FDA's clinical need Bulks List, or the drug made from it is on the shortage list. A practice sourcing under 503A never had a shortage lane to lose.

Not as a copy of the approved drug. The exception letting an outsourcing facility make a drug identical or nearly identical to an approved product runs on the shortage listing and closes when the listing does. The individual-patient clinical-difference language is a different prong, reaching drugs compounded from a bulk substance that is a component of an approved drug. It is a finding about one patient, so it supports no menu item, package price or bulk order.

The state names the document. California requires a nurse practitioner working under standardized procedures to operate from a written standardized procedure jointly developed and approved by the supervising physician, the nurse practitioner and the facility administrator or a designee, covering which drugs and devices may be furnished, the extent of supervision and periodic competence review. Other states use different instruments, so find yours by section number.

As a cash exposure as much as a service one. Refund requests arrive in the same weeks the product does not, so the outstanding prepaid balance is a number worth holding each month. Selling shorter courses, or keeping the unearned portion apart from operating cash, stops a supply interruption from becoming a payroll problem. Settle refund terms in the service agreement before an interruption starts.

FDA proposed in May 2026 not to add semaglutide, tirzepatide or liraglutide to the 503B clinical need Bulks List, then extended the comment deadline to July 30, 2026. No final determination had published when this page was written in late August 2026. The shortage list moves independently of that docket, so check the list for the specific approved drug; the proposal's status is a different question.

Run your practice on Gale

The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.

Start or manage a practice →

References

  1. 1.Office of the Law Revision Counsel, U.S. House of Representatives (codifying FDCA Section 503B) (2023). 21 U.S.C. 353b - Outsourcing facilities. United States Code (2023 ed.), via GovInfo (U.S. Government Publishing Office). linkThe 503B 'essentially a copy' prohibition and its drug-shortage-list carve-out, the individual-patient clinical-difference carve-out, and the two lawful bulk-substance pathways that bound what an outsourcing facility may supply to a med spa.
  2. 2.Office of the Law Revision Counsel, U.S. House of Representatives (codifying FDCA Section 506E) (2023). 21 U.S.C. 356e - Drug shortage list. United States Code (2023 ed.), via GovInfo (U.S. Government Publishing Office). linkThat the 'shortage' the 503B exception turns on is a specific FDA-maintained public list, so a backorder or an allocation notice is not the trigger.
  3. 3.Office of the Law Revision Counsel, U.S. House of Representatives (codifying FDCA Section 503A) (2023). 21 U.S.C. 353a - Pharmacy compounding. United States Code (2023 ed.), via GovInfo (U.S. Government Publishing Office). linkThat a 503A pharmacist or physician compounder has no shortage exception at all, and that its single escape from the 'essentially a copy' bar is a prescriber-determined significant difference for one identified patient.
  4. 4.Food and Drug Administration, U.S. Department of Health and Human Services (2026). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Federal Register, 91 FR 23431 (May 1, 2026); Docket FDA-2018-N-3240. link ✓FDA's May 2026 tentative finding of no clinical need to compound with semaglutide, tirzepatide or liraglutide, the first threshold question in its clinical need test, and its statement that FDA-approved tirzepatide products are not on the drug shortage list.
  5. 5.Food and Drug Administration, U.S. Department of Health and Human Services (2026). List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period. Federal Register (June 26, 2026); Docket FDA-2018-N-3240. link ✓That the Bulks List proposal is not final, with the comment deadline extended to July 30, 2026, and the docket number a reader can follow for the outcome.
  6. 6.California Legislature (2011). California Business and Professions Code Section 2052. California Legislative Information (leginfo.legislature.ca.gov) — Business and Professions Code, Division 2, Chapter 5, Article 12 (Unlicensed Practice). link ✓The California penalty for practicing medicine without a license or aiding someone who does, as one worked state example of what a delegation error costs.
  7. 7.California Legislature (2018). California Business and Professions Code Section 2836.1. California Legislative Information (leginfo.legislature.ca.gov) — Business and Professions Code, Division 2, Chapter 6, Article 2 (Nursing Practice Act). link ✓The California written standardized procedure requirement, its named signatories and its required contents, as the concrete delegation document a med spa either holds or does not.

https://www.gale.care/for-providers/se-medspa-compounded-glp1-lane · 7 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.

← Back to for providers

Findability, by specialty

How practices like yours get found in local search and AI answers — the honest playbook, per specialty.

SEO for private practices · SEO for AI search / answer engines (all verticals)